Are the stars lining up for a major M&A deal at Novartis?
Two big things are going on right now at Novartis that have the investor crowd on high alert.
First, CEO Vas Narasimhan has signaled he’s now ready to sell or spin off the big generics arm, Sandoz. In Big Pharma land, anything that drags on performance — like consumer arms with aging therapeutics — is being hived off as organizations zero in on innovation as the future.
Second, they just sold that big block of Roche shares for $21 billion. And what do they plan to do with all that money?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.